[Click eStock] "Biol, Rapid Growth Expected in China"

On the 4th, LS Securities forecasted that Biol's sales would increase in Asian regions such as China and Japan.

Biol recorded sales of 17.7 billion KRW and operating profit of 11 billion KRW in the fourth quarter of last year. This represents an increase of 54% and 90%, respectively, compared to the same period the previous year.

Jo Eun-ae, a researcher at LS Securities, explained, "Biol achieved results exceeding market expectations in the fourth quarter of last year," adding, "Since the second quarter of last year, sales of SilfirmX and Scarlet to China have recorded over 1 billion KRW per quarter."

She continued, "This year, we expect a full-scale expansion of the distribution network for SilfirmX in China," and added, "As sales volume increases, rapid growth will continue."

Researcher Jo estimated, "Considering the recovery of relatively sluggish sales in the United States and the increase in sales in Asian regions such as China, Japan·and Thailand, sales this year are expected to increase by 20% compared to last year." She emphasized, "Biol's current stock price is at a price-to-earnings ratio (PER) of about 13 times based on this year's expected performance," and "it is undervalued compared to the industry average of 18 times."

However, reflecting the decline in multiples of peer groups, she lowered the target stock price from the previous 14,000 KRW to 12,000 KRW.

This content was produced with the assistance of AI translation services.